TICKERNERD
Menu
CUECUEHealthcare · Biotechnology

CUE Stock Forecast: Cue Biopharma, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$19
−0.32% on the day

The 3 Wall Street analysts covering Cue Biopharma, Inc. hold a median 12-month price target of $83 — +339.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 21 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$137.7M
Ticker Nerd rank
37/ 100
Median analyst target
$83
Analysts covering
3
Revenue$7.9M+166.7% y/y
Operating income−$87.7M
Net income−$153.1M
Free cash flow−$29.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.2%
1M
−38.9%
YTD
+106.4%
1Y
−17.7%
From 52W high
−50.1%
From 52W low
+255.7%
$5
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CUE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cue Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
37/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
97
Size
70
Momentum
65
Value
58
Revisions
35
Growth
35
Quality
28
Issuance
11
Volatility
7

Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (7): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CUE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CUE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100$120Jan 26Apr 26Jul 26Oct 26CUEHigh $115Median $83Low $66

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $66Median $83High $115

The green dot is the last close — the median target sits +339.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Sept 2026B. Riley SecuritiesInitiatesBuy$83
25 Aug 2025LUCID CAPITAL MARKETSInitiatesBuy$4.00
25 Aug 2025LUCID CAPITAL MARKETSInitiatesBuy—
2 Apr 2025Citizens Capital MarketsReiteratesMarket Outperform—
20 Aug 2024StifelMaintainsBuy—
26 July 2024JMP SecuritiesMaintainsMarket Outperform—
26 July 2024Piper SandlerMaintainsOverweight—
9 Apr 2024OppenheimerMaintainsOutperform—
9 Apr 2024StifelMaintainsBuy—
3 Apr 2024Piper SandlerReiteratesOverweight—
13 Mar 2024JefferiesInitiatesBuy—
6 Nov 2023Piper SandlerMaintainsOverweight—
26 June 2023OppenheimerAssumesOutperform$10
15 June 2023StifelReiteratesBuy—
15 May 2023JMP SecuritiesReiteratesOutperform—
22 Mar 2023OppenheimerReiteratesOutperform—
22 Mar 2023StifelMaintainsBuy—
21 Nov 2022Piper SandlerInitiatesOverweight—
24 Aug 2022OppenheimerMaintainsOutperform—
21 Mar 2022OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CUE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

CUE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Cue Biopharma, Inc. returned −17.7% against +15.6% for the S&P 500, dividends included.

CUE vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26CUES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CUE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Cue Biopharma, Inc. (CUE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.3×

Cheaper than 86% of US stocks

Price / sales
3.7×

Cheaper than 33% of US stocks

Price / book
42.9×

Cheaper than 2% of US stocks

EV / EBITDA
−1.3×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
166.7%

Higher than 95% of US stocks

Earnings growth (YoY)
166.7%

Higher than 89% of US stocks

Gross margin
—
Operating margin
−1113.3%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1603.5%

Higher than 1% of US stocks

Return on assets
−172.7%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cue Biopharma, Inc. (CUE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cue Biopharma, Inc. has a market value of $137.7M and an enterprise value of $123.3M.

  • Revenue in the twelve months to 30 June 2026: $37.7M. The latest quarter grew 166.7% year on year.

  • Net income over the same four quarters: −$164.1M, a −435.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−27.02.

  • Free cash flow in the twelve months to 30 June 2026: −$50.2M.

  • Shares outstanding: 5.2M.

  • Trailing P/E: −2.3×; forward P/E: −39.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cue Biopharma, Inc. employs 29 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

CUE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CUECue Biopharma, Inc.$137.7M37
OTLKOutlook Therapeutics, Inc.$136.6M5
CDXSCodexis, Inc.$138.8M62
MENSJyong Biotech Ltd.$140.3M3
KRROKorro Bio, Inc.$134.0M33
PDSBPDS Biotechnology Corp.$130.2M77
TLSATiziana Life Sciences Ltd. (Bermuda)$129.6M21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cue Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CUE news & analysis

Cue Biopharma's CUE-221 Hits Phase II Goals, Shows Durable CSU Response

MarketBeat · 28 Sept 2026positive

Cue Biopharma reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria that was inadequately controlled with H1 antihistamines. The trial met its Phase II goals, demonstrating a durable response.

Why it matters — These positive Phase II results represent a meaningful clinical milestone for CUE-221 and could advance the drug's development in chronic spontaneous urticaria.

Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA

Seeking Alpha · 21 Sept 2026positive

An analyst initiated coverage of Cue Biopharma with a "Buy" rating, citing positive phase 2 results for CUE-221 in chronic spontaneous urticaria, where the drug's novel dual mechanism showed superior efficacy to XOLAIR with 54% of patients achieving complete hive resolution at 12 weeks. Upcoming catalysts include 36-week PK and IgE data in 2026 and planned phase 2b/3 global studies.

Why it matters — CUE watchers would care because positive phase 2 data for CUE-221 and its planned late-stage studies signal potential pipeline progress in large-market indications like CSU and food allergy.

Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript

Seeking Alpha · 21 Sept 2026positive

The article covers a transcript of Cue Biopharma discussing positive Phase II top line results for CUE-221 in treating chronic spontaneous urticaria. The company reported favorable outcomes from the trial.

Why it matters — A CUE watcher would care because positive Phase II results for CUE-221 represent a key clinical milestone for the company's pipeline in chronic spontaneous urticaria.

What's Going on With Cue Biopharma Stock on Monday?

Benzinga · 21 Sept 2026neutral

Cue Biopharma announced topline results from a Phase 2 trial of CUE-221 in patients with moderate to severe chronic spontaneous urticaria, prompting questions about the company's stock move on Monday.

Why it matters — This trial update provides early clinical data on CUE-221, a key pipeline candidate, and is directly relevant to investors tracking the company's development progress.

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

GlobeNewsWire · 20 Sept 2026positive

Cue Biopharma announced positive topline results from its CUE-221 Phase 2 study in chronic spontaneous urticaria. The company said the results support a potentially differentiated clinical impact for patients with chronic hives and advancement to a Phase 2b/3 registration-enabling study.

Why it matters — For Cue Biopharma watchers, the positive Phase 2 topline data and planned advancement to a registration-enabling study mark an important clinical milestone for its CUE-221 program in chronic spontaneous urticaria.

FAQ

Frequently asked questions about CUE stock

What is the CUE stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Cue Biopharma, Inc. have a median 12-month price target of $83, with estimates ranging from $66 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CUE stock a buy right now?

Of the 3 analysts covering Cue Biopharma, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cue Biopharma, Inc. 37 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CUE?

As at 21 Oct 2026, Cue Biopharma, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).

Will CUE stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +339.4% from the last close, and Ticker Nerd's factor model ranks Cue Biopharma, Inc. 37 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CUE stock forecast for 2030?

No analyst covering Cue Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CUE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $66 to $115 over the next 12 months.

How has CUE stock performed over the past year?

Cue Biopharma, Inc. returned -17.7% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cue Biopharma, Inc. do?

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision immunotherapies for allergic and autoimmune diseases.

What is the latest news on CUE?

The most recent item we track (MarketBeat, 28 Sept 2026): "Cue Biopharma's CUE-221 Hits Phase II Goals, Shows Durable CSU Response". Cue Biopharma reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria that was inadequately controlled with H1 antihistamines. The trial met its Phase II goals, demonstrating a durable response.

Company

About Cue Biopharma, Inc.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision immunotherapies for allergic and autoimmune diseases. Its current portfolio centers on therapeutic biologics designed to selectively modulate disease-specific T cells and restore immune balance without broad immune suppression. The company’s lead asset, CUE-221, is an anti-IgE antibody being advanced for allergic diseases, while CUE-401 is a bifunctional IL-2 and TGF-β program designed to support Treg-mediated tolerance in autoimmune conditions. Cue Biopharma’s Immuno-STAT platform underpins its product development approach, enabling targeted immune modulation across immunological disorders. Based in Boston, Massachusetts, Cue Biopharma participates in the biotechnology sector through a pipeline aimed at addressing unmet medical needs in allergy, inflammation, and autoimmunity.

CEO Dr. Shao-Lee Lin M.D., Ph.D. · 29 employees · United States · https://www.cuebiopharma.com